U.S. markets closed
  • S&P Futures

    4,150.50
    -3.00 (-0.07%)
     
  • Dow Futures

    33,147.00
    -8.00 (-0.02%)
     
  • Nasdaq Futures

    14,037.75
    +2.75 (+0.02%)
     
  • Russell 2000 Futures

    2,231.40
    +0.80 (+0.04%)
     
  • Crude Oil

    71.84
    +0.20 (+0.28%)
     
  • Gold

    1,768.30
    -0.70 (-0.04%)
     
  • Silver

    25.92
    -0.05 (-0.19%)
     
  • EUR/USD

    1.1876
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3820
    +0.0011 (+0.08%)
     
  • USD/JPY

    110.1780
    +0.0280 (+0.03%)
     
  • BTC-USD

    35,721.54
    +158.27 (+0.45%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.22 (-0.19%)
     
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer begins early-stage study of oral COVID-19 drug

·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

March 23 (Reuters) - Pfizer Inc has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on Tuesday.

The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SA, said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies.

Pfizer's candidate, named PF-07321332, is a protease inhibitor that prevents the virus from replicating in cells.

Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both on their own and in combination with other antivirals, the company said.

Pfizer believes this class of molecules may provide well-tolerated treatments against COVID-19, as currently marketed therapeutics that work on the same lines have not reported safety concerns.

The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients.

"Together, the two (oral and intravenous candidates) have the potential to create an end-to-end treatment paradigm that complements vaccination in cases where disease still occurs," Pfizer's Chief Medical Officer Mikael Dolsten said in a statement.

Pfizer's candidate is behind two other oral antiviral therapies, which are in mid-stage trials – the first being developed by rival Merck & Co with Ridgeback Bio, and a second from Roche Holding and Atea Pharmaceuticals.

Gilead Sciences' remdesivir is currently the only U.S. Food and Drug Administration-approved drug for the treatment of COVID-19.

The FDA has granted an emergency authorization to intravenous therapies from Eli Lilly - bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron. (Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)